GCAT definition
Examples of GCAT in a sentence
GCAT shall be responsible for and shall file and own all Drug Approval Applications in the Territory.
If such award is obtained by GCAT and such award is in excess of both Parties’ costs, expenses and associated [**] percent ([**]%) premium, the amount of such excess shall be considered Net Sales in the Calendar Quarter it is received for purposes of calculating royalties payable by GCAT in accordance with Section 7.2 if the recovery is for infringement by a product that is competitive to a Licensed Product.
GCAT shall thereafter be solely responsible for the chemistry, manufacturing and control (“CMC”) of Elvucitabine in the Commercialization Field in the Territory, clinical supplies and Licensed Products.
The Company has delivered Schedule 5.01(h) to the Agent setting forth the amount, terms, and provider(s) to the Company of reinsurance and the extent of the Company’s insurance or reinsurance exposure covered thereby; as of December 31, 2004, Schedule 5.01(h) is correct and complete and fairly represents the reinsurance coverage pertaining to the business of the Company and its Subsidiaries (“Existing Reinsurance Coverage”).
The Development Plan shall be updated by GCAT and submitted to Achillion for review on or before the [**] day of each Calendar Quarter during the Term of the Agreement, so long as a clinical study for Elvucitabine and/or Licensed Product is being conducted by or on behalf of GCAT in the Territory.
GCAT shall be solely responsible, at its sole expense, for marketing and commercialization of Licensed Products in the Territory.
GCAT shall give due consideration to all comments by Achillion to the Commercialization Plan, and make those revisions and adjustments to the Commercialization Plan reasonably requested by Achillion.
GCAT shall be solely responsible for the export/import of the Research Drug Substance and the Development Drug Substance to the Territory for use in accordance with the Agreement, and all costs related thereto.
The exclusive license grants GCAT the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, (TIPR) to clinically develop and commercialize elvucitabine in mainland China, Hong Kong, and Taiwan.
All costs and expenses for the Development Program shall be paid in full by GCAT.